COVID-19 Pandemic Impact on Surgical Treatment Methods for Early-Stage Cervical Cancer: A Population-Based Study in Romania

• Published in: Healthcare (Basel) Vol. 10; no. 4; p. 639
• Main Authors: Popescu, Alin, Craina, Marius, Pantea, Stelian, Pirvu, Catalin, Radu, Daniela, Marincu, Iosif, Bratosin, Felix, Bogdan, Iulia, Hosin, Samer, Citu, Cosmin, Bernad, Elena, Neamtu, Radu, Dumitru, Catalin, Mocanu, Adelina Geanina, Gluhovschi, Adrian
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28-03-2022; MDPI
• Subjects: Cancer therapies; Cellular biology; Cervical cancer; Chemotherapy; Coronaviruses; COVID-19; disease-free survival; Gynecology; Hysterectomy; Infections; Medical research; Metastasis; Mortality; Obstetrics; Pandemics; Patients; Population; Population-based studies; Radiation therapy; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Surgery; Survival analysis; Romania; COVID-19; SARS-CoV-2; disease-free survival; cervical cancer; hysterectomy
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare10040639

Being one of the most common malignancies in young women, cervical cancer is frequently successfully screened around the world. Early detection enables for an important number of curative options that allow for more than 90% of patients to survive more than three years without cancer relapse. Unfortunately, the COVID-19 pandemic put tremendous pressure on healthcare systems and access to cancer care, determining us to develop a study on the influence the pandemic had on surgical care of cervical cancer, and to assess changes in its management and outcomes. A retrospective study design allowed us to compare cervical cancer trends of the last 48 months of the pre-pandemic period with the first 24 months during the COVID-19 pandemic, using the database from the Timis County Emergency Clinical Hospital. New cases of cervical cancer presented to our clinic in more advanced stages (34.6% cases of FIGO stage III during the pandemic vs. 22.4% before the pandemic,
-value = 0.047). These patients faced significantly more changes in treatment plans, postponed surgeries, and postponed radio-chemotherapy treatment. From the full cohort of cervical cancer patients, 160 were early stages eligible for curative intervention who completed a three-year follow-up period. The disease-free survival and overall survival were not influenced by the surgical treatment of choice, or by the SARS-CoV-2 infection (log-rank
-value = 0.449, respectively log-rank
-value = 0.608). The individual risk factors identified for the three-year mortality risk were independent of the SARS-CoV-2 infection and treatment changes during the COVID-19 pandemic. We observed significantly fewer cases of cervical cancer diagnosed per year during the first 24 months of the COVID-19 pandemic, blaming the changes in healthcare system regulations that failed to offer the same conditions as before the pandemic. Even though we did not observe significant changes in disease-free survival of early-stage cervical cancers, we expect the excess of cases diagnosed in later stages to have lower survival rates, imposing the healthcare systems to consider different strategies for these patients while the pandemic is still ongoing.